CN103946237B - 白蛋白结合抗体及其结合片段 - Google Patents
白蛋白结合抗体及其结合片段 Download PDFInfo
- Publication number
- CN103946237B CN103946237B CN201280055064.0A CN201280055064A CN103946237B CN 103946237 B CN103946237 B CN 103946237B CN 201280055064 A CN201280055064 A CN 201280055064A CN 103946237 B CN103946237 B CN 103946237B
- Authority
- CN
- China
- Prior art keywords
- antibody
- variable domains
- seq
- chain
- heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
Abstract
Description
SEQ ID NO: | 序列 |
21 | SGGGGSE |
22 | DKTHTS |
23 | (S)GGGGS |
24 | (S)GGGGSGGGGS |
25 | (S)GGGGSGGGGSGGGGS |
26 | (S)GGGGSGGGGSGGGGSGGGGS |
27 | (S)GGGGSGGGGSGGGGSGGGGSGGGGS |
28 | AAAGSG-GASAS |
29 | AAAGSG-XGGGS-GASAS |
30 | AAAGSG-XGGGSXGGGS-GASAS |
31 | AAAGSG-XGGGSXGGGSXGGGS-GASAS |
32 | AAAGSG-XGGGSXGGGSXGGGSXGGGS-GASAS |
33 | AAAGSG-XS-GASAS |
34 | PGGNRGTTTTRRPATTTGSSPGPTQSHY |
35 | ATTTGSSPGPT |
36 | ATTTGS |
- | GS |
37 | EPSGPISTINSPPSKESHKSP |
38 | GTVAAPSVFIFPPSD |
39 | GGGGIAPSMVGGGGS |
40 | GGGGKVEGAGGGGGS |
4l | GGGGSMKSHDGGGGS |
42 | GGGGNLITIVGGGGS |
43 | GGGGVVPSLPGGGGS |
44 | GGEKSIPGGGGS |
45 | RPLSYRPPFPFGFPSVRP |
46 | YPRSlYIRRRHPSPSLTT |
47 | TPSHLSHILPSFGLPTFN |
48 | RPVSPFTFPRLSNSWLPA |
49 | SPAAHFPRSIPRPGPIRT |
50 | APGPSAPSHRSLPSRAFG |
51 | PRNSIHFLHPLLVAPLGA |
52 | MPSLSGVLQVRYLSPPDL |
53 | SPQYPSPLTLTLPPHPSL |
54 | NPSLNPPSYLHRAPSRIS |
55 | LPWRTSLLPSLPLRRRP |
56 | PPLFAKGPVGLLSRSFPP |
57 | VPPAPVVSLRSAHARPPY |
58 | LRPTPPRVRSYTCCPTP- |
59 | PNVAHVLPLLTVPWDNLR |
60 | CNPLLPLCARSPAVRTFP |
SEQ ID NO: | 序列 |
63 | DKTHTCAA |
64 | DKTHTCPPCPA |
65 | DKTHTCPPCPATCPPCPA |
66 | DKTHTCPPCPATCPPCPATCPPCPA |
67 | DKTHTCPPCPAGKPTLYNSLVMSDTAGTCY |
68 | DKTHTCPPCPAGKPTHVNVSVVMAEVDGTCY |
69 | DKTHTCCVECPPCPA |
70 | DKTHTCPRCPEPKSCDTPPPCPRCPA |
71 | DKTHTCPSCPA |
Claims (12)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161558559P | 2011-11-11 | 2011-11-11 | |
US61/558,559 | 2011-11-11 | ||
PCT/EP2012/072335 WO2013068571A1 (en) | 2011-11-11 | 2012-11-09 | Albumin binding antibodies and binding fragments thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103946237A CN103946237A (zh) | 2014-07-23 |
CN103946237B true CN103946237B (zh) | 2017-04-12 |
Family
ID=47358092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280055064.0A Active CN103946237B (zh) | 2011-11-11 | 2012-11-09 | 白蛋白结合抗体及其结合片段 |
Country Status (24)
Country | Link |
---|---|
US (2) | US9803004B2 (zh) |
EP (1) | EP2776466B1 (zh) |
JP (1) | JP6411214B2 (zh) |
KR (1) | KR102048382B1 (zh) |
CN (1) | CN103946237B (zh) |
AU (1) | AU2012335496B2 (zh) |
BR (1) | BR112014011304B1 (zh) |
CA (1) | CA2856216C (zh) |
CY (1) | CY1119647T1 (zh) |
DK (1) | DK2776466T3 (zh) |
EA (1) | EA033766B1 (zh) |
ES (1) | ES2649098T3 (zh) |
HR (1) | HRP20171608T1 (zh) |
HU (1) | HUE037142T2 (zh) |
IL (1) | IL232226B (zh) |
IN (1) | IN2014DN03451A (zh) |
LT (1) | LT2776466T (zh) |
MX (1) | MX351502B (zh) |
NO (1) | NO2839445T3 (zh) |
PL (1) | PL2776466T3 (zh) |
PT (1) | PT2776466T (zh) |
SG (1) | SG11201401649VA (zh) |
SI (1) | SI2776466T1 (zh) |
WO (1) | WO2013068571A1 (zh) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
CA2922618C (en) * | 2013-08-30 | 2020-04-28 | Aprilbio Co., Ltd | An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
WO2016179517A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
EP3319984A1 (en) | 2015-07-06 | 2018-05-16 | UCB Biopharma SPRL | Tau-binding antibodies |
AU2016289755C1 (en) | 2015-07-06 | 2021-08-19 | UCB Biopharma SRL | Tau-binding antibodies |
WO2017060242A1 (en) | 2015-10-05 | 2017-04-13 | Ucb Biopharma Sprl | Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases |
TWI717432B (zh) | 2015-12-02 | 2021-02-01 | 美商艾吉納斯公司 | 抗體和使用彼之方法 |
GB201602938D0 (en) | 2016-02-19 | 2016-04-06 | Ucb Biopharma Sprl | Protein purification |
BR112018071288A2 (pt) * | 2016-05-01 | 2019-02-26 | Ucb Biopharma Sprl | dominio de ligação de carreador de proteína sérica de afinidade modificada |
GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
US11028166B2 (en) | 2017-02-16 | 2021-06-08 | Sonnet Bio Therapeutics | Albumin binding domain fusion proteins |
US11365240B2 (en) | 2017-06-05 | 2022-06-21 | Numab Therapeutics AG | Anti-HSA antibodies |
WO2018224439A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
GB201711481D0 (en) | 2017-07-17 | 2017-08-30 | Ucb Biopharma Sprl | Protein purification |
KR102204315B1 (ko) * | 2018-11-16 | 2021-01-18 | 한국세라믹기술원 | 인간 혈청 알부민에 특이적으로 결합하는 어피바디 및 그의 용도 |
SG11202112846RA (en) | 2019-08-02 | 2021-12-30 | UCB Biopharma SRL | Methods for purifying antibodies |
CN112409480A (zh) * | 2019-08-20 | 2021-02-26 | 四川科伦博泰生物医药股份有限公司 | 结合血清白蛋白的蛋白及其用途 |
GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
IL296732A (en) | 2020-03-27 | 2022-11-01 | UCB Biopharma SRL | Autonomous knob domain peptides |
KR102367488B1 (ko) * | 2020-06-29 | 2022-02-25 | 주식회사 프로테인웍스 | 단일사슬항체-알부민 약물 복합체의 분석방법 |
KR20230087552A (ko) | 2020-10-15 | 2023-06-16 | 유씨비 바이오파마 에스알엘 | Cd45를 다량체화하는 결합 분자 |
CN116670166A (zh) | 2020-12-07 | 2023-08-29 | Ucb生物制药有限责任公司 | 多特异性抗体和抗体组合 |
IL303294A (en) | 2020-12-07 | 2023-07-01 | UCB Biopharma SRL | Antibodies against interleukin-22 |
CN115181751A (zh) * | 2021-04-02 | 2022-10-14 | 苏州博腾生物制药有限公司 | 靶向白蛋白的嵌合抗原受体及其使用方法 |
WO2022233764A1 (en) | 2021-05-03 | 2022-11-10 | UCB Biopharma SRL | Antibodies |
TW202313685A (zh) * | 2021-06-07 | 2023-04-01 | 大陸商上海濟煜醫藥科技有限公司 | 抗人血清白蛋白的抗原結合蛋白 |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
TW202409093A (zh) | 2022-06-15 | 2024-03-01 | 比利時商Ucb生物製藥公司 | 融合蛋白 |
WO2023242271A1 (en) | 2022-06-15 | 2023-12-21 | UCB Biopharma SRL | Fusion protein for the prevention, treatment or amelioration of kidney diseases |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
WO1992018619A1 (en) | 1991-04-10 | 1992-10-29 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
DE69334258D1 (de) | 1992-08-21 | 2009-02-26 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
DE19653722C2 (de) | 1996-12-10 | 2000-06-29 | Brose Fahrzeugteile | Beidseitig wirkende Verstellvorrichtung |
DK0968291T3 (da) | 1997-02-21 | 2004-06-07 | Genentech Inc | Antistoffragment-polymerkonjugater |
GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
WO1999037791A1 (en) | 1998-01-23 | 1999-07-29 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Multipurpose antibody derivatives |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
PT1240337E (pt) | 1999-12-24 | 2007-01-31 | Genentech Inc | Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos |
JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
AU2003245664A1 (en) | 2002-06-21 | 2004-01-06 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
CA2507004A1 (en) | 2002-12-03 | 2004-06-17 | Celltech R & D Limited | Assay for identifying antibody producing cells |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
CA2527020A1 (en) | 2003-07-01 | 2005-01-13 | Celltech R & D Limited | Modified antibody fab fragments |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
KR20120133403A (ko) | 2004-06-01 | 2012-12-10 | 도만티스 리미티드 | 증강된 혈청 반감기를 가지는 이특이성 융합 항체 |
WO2006059105A2 (en) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Non-cytotoxic Protein Conjugates |
GB0506912D0 (en) | 2005-04-05 | 2005-05-11 | Celltech R&D Ltd | Biological products |
CN104004088B (zh) * | 2007-09-26 | 2017-11-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
MY157473A (en) | 2009-02-17 | 2016-06-15 | Ucb Biopharma Sprl | Antibody molecules having specificity for human ox40 |
AU2010272590B2 (en) | 2009-07-16 | 2013-10-10 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
ES2667258T3 (es) * | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
GB201005063D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
-
2012
- 2012-11-09 MX MX2014005546A patent/MX351502B/es active IP Right Grant
- 2012-11-09 EA EA201400568A patent/EA033766B1/ru not_active IP Right Cessation
- 2012-11-09 EP EP12801467.7A patent/EP2776466B1/en active Active
- 2012-11-09 AU AU2012335496A patent/AU2012335496B2/en active Active
- 2012-11-09 DK DK12801467.7T patent/DK2776466T3/da active
- 2012-11-09 SI SI201231119T patent/SI2776466T1/sl unknown
- 2012-11-09 ES ES12801467.7T patent/ES2649098T3/es active Active
- 2012-11-09 SG SG11201401649VA patent/SG11201401649VA/en unknown
- 2012-11-09 HU HUE12801467A patent/HUE037142T2/hu unknown
- 2012-11-09 JP JP2014540494A patent/JP6411214B2/ja active Active
- 2012-11-09 PT PT128014677T patent/PT2776466T/pt unknown
- 2012-11-09 PL PL12801467T patent/PL2776466T3/pl unknown
- 2012-11-09 CN CN201280055064.0A patent/CN103946237B/zh active Active
- 2012-11-09 LT LTEP12801467.7T patent/LT2776466T/lt unknown
- 2012-11-09 US US14/356,181 patent/US9803004B2/en active Active
- 2012-11-09 KR KR1020147015678A patent/KR102048382B1/ko active IP Right Grant
- 2012-11-09 CA CA2856216A patent/CA2856216C/en active Active
- 2012-11-09 BR BR112014011304-1A patent/BR112014011304B1/pt active IP Right Grant
- 2012-11-09 IN IN3451DEN2014 patent/IN2014DN03451A/en unknown
- 2012-11-09 WO PCT/EP2012/072335 patent/WO2013068571A1/en active Application Filing
-
2013
- 2013-04-12 NO NO13716781A patent/NO2839445T3/no unknown
-
2014
- 2014-04-24 IL IL23222614A patent/IL232226B/en active IP Right Grant
-
2017
- 2017-10-23 HR HRP20171608TT patent/HRP20171608T1/hr unknown
- 2017-10-27 US US15/795,874 patent/US10023631B2/en active Active
- 2017-11-22 CY CY20171101222T patent/CY1119647T1/el unknown
Non-Patent Citations (1)
Title |
---|
Anti-serum albumin domain antibodies for extending the half-life of short lived drugs;Lucy J Holt et al;《Protein Engineering,Design and Selection》;20080101;283-288 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103946237B (zh) | 白蛋白结合抗体及其结合片段 | |
CN102164965B (zh) | 生物产品 | |
KR102271204B1 (ko) | 다중특이적 항체 작제물 | |
CN104004088B (zh) | 双特异性抗体融合物 | |
CN102549018B (zh) | 二硫键稳定的多价抗体 | |
CN103384682B (zh) | 结合il‑17a和il‑17f的抗体分子 | |
CN106459217A (zh) | 多特异性抗体构建体 | |
CN106661112A (zh) | 具有针对cd45和cd79的特异性的分子 | |
US11999772B2 (en) | Antibodies comprising a polypeptide inserted in framework 3 region | |
JP6898251B2 (ja) | 組換え抗体分子の単量体化方法 | |
JP6901402B2 (ja) | 単量体抗体Fab−dsFv多量体種のパーセンテージを増加させる方法 | |
RU2796254C2 (ru) | Антитела, содержащие полипептид, встроенный в участок каркасной области 3 | |
AU2019302995B9 (en) | Antibodies comprising a polypeptide inserted in framework 3 region |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1196620 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180809 Address after: Brussels Patentee after: UCB PHARMA SA Address before: Brussels Patentee before: UCB Pharma SA |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Brussels Patentee after: UCB biopharmaceutical Co.,Ltd. Address before: Brussels Patentee before: UCB BIOPHARMA SPRL |